Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359672 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL15447800 | 0.97 | CYP3A4 (0.58) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL12234456 | 0.95 | CYP3A4 (0.52) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL20484245 | 0.95 | CYP3A4 (0.52) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL12234455 | 0.95 | CYP3A4 (0.52) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL1359250 | 0.94 | CYP3A4 (0.57) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL1359255 | 0.94 | CYP3A4 (0.57) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL14482578 | 0.93 | CYP3A4 (0.47) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL14482560 | 0.93 | CYP3A4 (0.47) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL15448419 | 0.92 | CYP3A4 (0.55) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499132-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-02-15 | — | — | EP | claimed |
| US-20140018389-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-01-16 | — | — | US | claimed |
| US-20130012540-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-10 | — | — | US | claimed |
| EP-2499132-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-09-19 | — | — | EP | claimed |
| EP-2499132-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-02-15 | — | — | EP | disclosed |
| US-20140018389-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-01-16 | — | — | US | disclosed |
| US-8618153-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130012540-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-10 | — | — | US | disclosed |
| US-20110281910-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281910-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CYP3A4 3600/4885CYP2C9 4154/4885NR1I2 693/4885 |
| US-20130012540-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CYP3A4 3600/4885CYP2C9 4154/4885NR1I2 693/4885 |
| US-20140018389-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CYP3A4 3600/4885CYP2C9 4154/4885NR1I2 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.